Dose Dense Cyclophosphamide, Methotrexate, Fluorouracil is Feasible at 14-Day Intervals: A Pilot Study of Every-14-Day Dosing as Adjuvant Therapy for Breast Cancer

PURPOSE: Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer. Randomized trials with other regimens demonstrate that dose-dense (DD) scheduling can offer greater efficacy. We investigated the feasibility of administering CMF using...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Drullinsky, Pamela, Sugarman, Steven M., Fornier, Monica N., D’Andrea, Gabriella, Gilewski, Teresa, Lake, Diana, Traina, Tiffany, Wasserheit-Lieblich, Carolyn, Sklarin, Nancy, Atieh-Graham, Deena, Mills, Nancy, Troso-Sandoval, Tiffany, Seidman, Andrew D., Yuan, Jeffrey, Patel, Hamangi, Patil, Sujata, Norton, Larry, Hudis, Clifford
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3661192/
https://ncbi.nlm.nih.gov/pubmed/21147686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CBC.2010.n.057
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars